Merck Completes Women’s Health Organon Spinoff
In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a standalone spinoff.
Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy
Oyster Point Pharma Inc (NASDAQ:OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene…
Histogen Stops HST 001 Development After Trial Failure, Shifts Focus On Programs For Orthopedic Indications
Histogen Inc (NASDAQ:HSTO) has decided to suspend the development of the HST 001 program after taking into consideration the results from…
Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings
Monopar Therapeutics Inc (NASDAQ:MNPR) collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs…
Adicet ClinicalTrials.gov Study Record Detail For Co.’s ‘Long-Term Follow-up Study for Subjects Treated With Adicet Bio T Cell Investigational Products,’ Shows Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT04911478
Mirum Pharma Highlights Presentation Of Analyses From Clinical Studies Evaluating Maralixibat In Patients With Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis Type 2
- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology.
- Safety data from
Zynerba Pharmaceuticals Announces Presentation Of Efficacy, Safety Findings In Children, Adolescents With Autism Spectrum Disorder (ASD) And Related Disorders At 2021 American Society Of Clinical Psychopharmacology Annual Meeting
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00
Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-killing ability of radiation.
COMPASS Pathways, Kings College London Publish Cognition Results From COMP360 Psilocybin Study In Healthy Volunteers
COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I